Human Predicted to work with:
Synthetic phosphopeptide derived from human NMDA or NR2A/B around the phosphorylation site of tyrosine 1246/1252 (N-L-YP-D-I).
Humna brain tissue; HuvEc cells
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS, 150mM Sodium chloride, pH 7.4
Without Mg2+ and Ca2+
Concentration information loading...
Immunogen affinity purified
This antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
1/500 - 1/1000.
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.
Involvement in disease
Defects in GRIN2A are the cause of epilepsy with neurodevelopmental defects (EPND) [MIM:613971]. EPND is a neurodevelopmental defect characterized by mental retardation, with behavioral problems, associated with epilepsy, learning difficuties and variable degree of cognitive impairment. Note=A chromosomal aberration involving GRIN2A has been found in a family with epilepsy and neurodevelopmental defects. Translocation t(16;17)(p13.2;q11.2). Note=GRIN2A somatic mutations have been frequently found in cutaneous malignant melanoma, suggesting that the glutamate signaling pathway may play a role in the pathogenesis of melanoma (PubMed:21499247).
Belongs to the glutamate-gated ion channel (TC 1.A.10.1) family. NR2A/GRIN2A subfamily.